title: A novel treatment approach for extensive, eruptive, cutaneous squamous cell carcinomas in a patient receiving BRAF inhibitor therapy for metastatic melanoma.
authors.forename: Ramin
authors.initials: R
authors.lastname: Fathi
authors.forename: Loebat
authors.initials: L
authors.lastname: Kamalpour
authors.forename: Bryan
authors.initials: B
authors.lastname: Gammon
authors.forename: Rebecca
authors.initials: R
authors.lastname: Tung
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000473:pathology* / Q000628:therapy*; D003131:Combined Modality Therapy; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D008297:Male; D008545:Melanoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D015580:Mohs Surgery; D009361:Neoplasm Invasiveness; D010778:Photochemotherapy; D048493:Proto-Oncogene Proteins B-raf; D012878:Skin Neoplasms / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D013449:Sulfonamides / Q000009:adverse effects*; D000077484:Vemurafenib
chemical_list: D000964:Antimetabolites, Antineoplastic; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D005472:Fluorouracil